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INTRODUCTION:
Synovial sarcoma, which has been named after its
microscopic resemblance to normal synovium, is a
rare and aggressive malignancy of soft tissues that
usually occurs in close proximity to large joints of
the extremities though it may be found in almost any
part of the body.1 Its occurrence in the mediastinum
was first reported in the early 1990s.2 Genetic factors,
specially chromosomal translocation t(X;18) (p11;q11)
are believed to influence the development of this
disease.1,2 Synovial sarcoma represents between
5% and 10% of all soft tissue sarcomas. Herein one
such case is reported.
CASE REPORT:
An 18 year male presented with complaint of pain in
right side of the chest for one year, not associated
with fever, weight loss or hemoptysis. On examination,
patient was of average height and thin built with
normal vitals. Examination of the chest showed
decreased movements, dull percussion note and
absent breath sounds in right lower zone. Rest of
the systemic examination was unremarkable.
Chest x-ray showed a homogenous opacity in the
right middle and lower zones (Fig-I). C.T scan chest
a soft tissue mass, 12 cm x 10 cm, in the right lower
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revealed hemithorax, with smooth margins and linear
calcification. No definite erosion of ribs or vertebrae
noted. Mass was obscuring the dome of diaphragm,
extending towards the posterior mediastinum and
para-vertebral region. Possibility of a large neurogenic
tumor or pleural based mass was suggested and tru-
cut biopsy was recommended for further evaluation.
Ultrasound guided tru-cut biopsy was done. It was
reported as neurofibroma.
After preoperative assessment, posterolateral
thoracotomy and excision of tumor was performed.
The tumor measured about 16 cm x 13 cm. It was
firm in consistency,  involving posterior mediastinum
The mediastinum is an uncommon site of synovial sarcoma which is a rare soft tissue
malignancy. An 18 year old boy was admitted for right sided chest pain since  one year.
Based on the CT scan chest findings, tru-cut biopsy of the mass was performed and
histopathology initially reported as neurofibroma. The tumor was excised via posterolateral
thoracotomy and excisional biopsy established the diagnosis of primary synovial sarcoma
arising from the mediastinum. Patient was started on adjuvant chemotherapy at the
oncologist tumor board’s recommendation and he received 6 cycles of adriamycin and
ifosfamide. At last follow up he is free of tumor recurrence.
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Fig-I: X-ray chest showing homogenous opacity
in right lower zone
adherent to the posterolateral chest wall, diaphragm
and lungs (Fig-II). It consisted of light brown
multinodular firm tissue, and the outer surface had
a dark brown haemorrhagic appearance.On
morphologic and immunohistochemical features, a
diagnosis of spindle cell synovial sarcoma was
made.
Postoperative recovery was smooth. The case was
discussed in multi-disciplinary tumor board meeting.
Board uniformly agreed to give 6 cycles of adjuvant
chemotherapy with adriamycin and ifosfamide.
Patient is on regular follow up without evidence of
residual or recurrent disease.
DISCUSSION:
The term synovial sarcoma is a misnomer because
the tumor does not arise from the synovium; it only
resembles synovial tissue on light microscopy. It
appears to arise from multipotent stem cells that
are capable of differentiating into mesenchymal
and/or epithelial structures and lack synovial
differentiation.1,2 
Only about 1-3 individuals in a million population
are diagnosed each year. This disease has the peak
incidence before the 30th birthday with male gender
prediclation.3 Our patient had similar characteristics.
Histologically, the tumor has been divided into four
different subtypes.4 The biphasic variant is composed
of spindle shaped fibroblast like cells and epitheloid
cells but majority of tumors are monophasic spindle
cell variety that  show either spindle cells only or
an epithelial component. Our patient was diagnosed
to have primary monphasic spindle cell synovial
sarcoma.
Surgical removal of tumor with clear margins followed
by radiotherapy or chemotherapy is the preferred
mode of treatment.  Synovial  sarcoma is a
chemosensit ive tumor. This was used as a
neoadjuvant therapy and for recurrence of the tumor.5
Spurrel et al and Spillane et al suggest that
chemotherapy with ifosfamide and doxorubicin have
the best response rates.4 Chemotherapy is highly
dependent on the size, grade and location of the
tumor. A study conducted by Ferrari et al reported
recurrence reduction following radiotherapy.6 In
general, with conventional fractionation  radiotherapy
doses between 50 and 70 Gy should be
administered.7
Traditionally, synovial sarcoma has been considered
to have a poor prognosis with metastasis occurring
in 50% of the cases. The lung is the most common
site for metastasis followed by lymph nodes and
bone. However, not all synovial sarcomas share the
same dismal outcome anymore. Spillane et al.
demonstrated that an age >20 year at diagnosis
and size > 5 cm were associated with a significantly
worse prognosis.3,8 However, prognosis after
aggressive multimodal therapy is good and survival
up to 14 years has been documented.5 The
mediastinum is an uncommon site of occurrence of
synovial sarcoma that occurred in index case.
Aggressive multimodal therapy is recommended
and our patient has responded to surgery and
chemotherapy.
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Fig-II:  A multinodular tumor removed at Thoracotomy
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